The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia

Małgorzata Urban-Kowalczyk,1 Magdalena Kotlicka-Antczak,1 Dominik Strzelecki,1 Ewa Rudecka,2 Janusz Śmigielski3 1Department of Affective and Psychotic Disorders, Medical University of Lodz, Lodz, Poland; 2Faculty of Human Nutrition and Consumer Sciences, Warsaw University of Life Sciences SGGW, Wars...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Urban-Kowalczyk M, Kotlicka-Antczak M, Strzelecki D, Rudecka E, Śmigielski J
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
Acceso en línea:https://doaj.org/article/1c0a9627fdbd48e6972bd4a02fdbd91c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:1c0a9627fdbd48e6972bd4a02fdbd91c
record_format dspace
spelling oai:doaj.org-article:1c0a9627fdbd48e6972bd4a02fdbd91c2021-12-02T12:17:50ZThe Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia1178-2021https://doaj.org/article/1c0a9627fdbd48e6972bd4a02fdbd91c2021-02-01T00:00:00Zhttps://www.dovepress.com/the-relationship-between-antipsychotic-treatment-and-plasma-beta-endor-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Małgorzata Urban-Kowalczyk,1 Magdalena Kotlicka-Antczak,1 Dominik Strzelecki,1 Ewa Rudecka,2 Janusz Śmigielski3 1Department of Affective and Psychotic Disorders, Medical University of Lodz, Lodz, Poland; 2Faculty of Human Nutrition and Consumer Sciences, Warsaw University of Life Sciences SGGW, Warsaw, Poland; 3State High Vocational School in Konin, Konin, PolandCorrespondence: Małgorzata Urban-KowalczykDepartment of Affective and Psychotic Disorders, Medical University of Lodz, Czechosłowacka 8/10, 92-216, Lodz, PolandTel +48 42 675 73 71Fax +48 42 675 74 03Email malgorzata.urban1@wp.plObjective: Some studies indicate the presence of elevated opioid levels in cases of schizophrenia and their relationship with negative symptoms. The pathogenesis of schizophrenia may be associated with an imbalance in the modulatory effect of opioids on the dopaminergic system. The aim of the study was to identify the association between β-endorphin (BE) concentration and the outcome of short-term schizophrenia treatment.Methods: We examined 49 patients hospitalized due to exacerbation of schizophrenia symptoms and 47 controls without schizophrenia. The severity of psychopathological symptoms was evaluated using Positive and Negative Syndrome Scale (PANSS) at the onset of hospitalization, and after four, six and ten weeks of treatment. Patients were classified into negative (NEG) and mixed (M) psychopathological subtypes according to the PANSS composite index. &Bgr;-endorphin (BE) plasma concentrations were assessed in all participants; in patients on inclusion to the study and after six weeks of treatment.Results: The patients with schizophrenia demonstrated higher BE levels than controls. During six-week antipsychotic treatment, BE concentration significantly increased in both NEG (p=0.000) and M (p=0.007), and positive symptoms were effectively reduced. In the NEG group, the prevalence of negative symptoms decreased only transiently and returned to approximately baseline values after 10 weeks (p=0.268). In the M patients, the prevalence of negative symptoms increased gradually (p=0.001), with more severe positive and, notably, negative symptoms correlating with higher BE2 concentrations at the 10-week assessment (R= 0.47, p= 0.0135 vs R= 0.74, p=0.0000). In both NEG and M, a greater rise in BE2 level correlated with a lower composite index during treatment.Conclusion: Patients with schizophrenia demonstrate higher BE levels compared to controls. These changes in BE concentration during antipsychotic treatment could reflect the interaction between dopaminergic transmission and endogenous opioids. A rise in BE level following effective antipsychotic therapy could be a potential predictor of persisting negative symptoms.Keywords: negative symptoms, endogenous opioids, schizophrenia, psychosisUrban-Kowalczyk MKotlicka-Antczak MStrzelecki DRudecka EŚmigielski JDove Medical Pressarticlenegative symptomsendogenous opioidsschizophreniapsychosisNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 17, Pp 503-512 (2021)
institution DOAJ
collection DOAJ
language EN
topic negative symptoms
endogenous opioids
schizophrenia
psychosis
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle negative symptoms
endogenous opioids
schizophrenia
psychosis
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Urban-Kowalczyk M
Kotlicka-Antczak M
Strzelecki D
Rudecka E
Śmigielski J
The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia
description Małgorzata Urban-Kowalczyk,1 Magdalena Kotlicka-Antczak,1 Dominik Strzelecki,1 Ewa Rudecka,2 Janusz Śmigielski3 1Department of Affective and Psychotic Disorders, Medical University of Lodz, Lodz, Poland; 2Faculty of Human Nutrition and Consumer Sciences, Warsaw University of Life Sciences SGGW, Warsaw, Poland; 3State High Vocational School in Konin, Konin, PolandCorrespondence: Małgorzata Urban-KowalczykDepartment of Affective and Psychotic Disorders, Medical University of Lodz, Czechosłowacka 8/10, 92-216, Lodz, PolandTel +48 42 675 73 71Fax +48 42 675 74 03Email malgorzata.urban1@wp.plObjective: Some studies indicate the presence of elevated opioid levels in cases of schizophrenia and their relationship with negative symptoms. The pathogenesis of schizophrenia may be associated with an imbalance in the modulatory effect of opioids on the dopaminergic system. The aim of the study was to identify the association between β-endorphin (BE) concentration and the outcome of short-term schizophrenia treatment.Methods: We examined 49 patients hospitalized due to exacerbation of schizophrenia symptoms and 47 controls without schizophrenia. The severity of psychopathological symptoms was evaluated using Positive and Negative Syndrome Scale (PANSS) at the onset of hospitalization, and after four, six and ten weeks of treatment. Patients were classified into negative (NEG) and mixed (M) psychopathological subtypes according to the PANSS composite index. &Bgr;-endorphin (BE) plasma concentrations were assessed in all participants; in patients on inclusion to the study and after six weeks of treatment.Results: The patients with schizophrenia demonstrated higher BE levels than controls. During six-week antipsychotic treatment, BE concentration significantly increased in both NEG (p=0.000) and M (p=0.007), and positive symptoms were effectively reduced. In the NEG group, the prevalence of negative symptoms decreased only transiently and returned to approximately baseline values after 10 weeks (p=0.268). In the M patients, the prevalence of negative symptoms increased gradually (p=0.001), with more severe positive and, notably, negative symptoms correlating with higher BE2 concentrations at the 10-week assessment (R= 0.47, p= 0.0135 vs R= 0.74, p=0.0000). In both NEG and M, a greater rise in BE2 level correlated with a lower composite index during treatment.Conclusion: Patients with schizophrenia demonstrate higher BE levels compared to controls. These changes in BE concentration during antipsychotic treatment could reflect the interaction between dopaminergic transmission and endogenous opioids. A rise in BE level following effective antipsychotic therapy could be a potential predictor of persisting negative symptoms.Keywords: negative symptoms, endogenous opioids, schizophrenia, psychosis
format article
author Urban-Kowalczyk M
Kotlicka-Antczak M
Strzelecki D
Rudecka E
Śmigielski J
author_facet Urban-Kowalczyk M
Kotlicka-Antczak M
Strzelecki D
Rudecka E
Śmigielski J
author_sort Urban-Kowalczyk M
title The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia
title_short The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia
title_full The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia
title_fullStr The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia
title_full_unstemmed The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia
title_sort relationship between antipsychotic treatment and plasma β-endorphin concentration in patients with schizophrenia
publisher Dove Medical Press
publishDate 2021
url https://doaj.org/article/1c0a9627fdbd48e6972bd4a02fdbd91c
work_keys_str_mv AT urbankowalczykm therelationshipbetweenantipsychotictreatmentandplasmabetaendorphinconcentrationinpatientswithschizophrenia
AT kotlickaantczakm therelationshipbetweenantipsychotictreatmentandplasmabetaendorphinconcentrationinpatientswithschizophrenia
AT strzeleckid therelationshipbetweenantipsychotictreatmentandplasmabetaendorphinconcentrationinpatientswithschizophrenia
AT rudeckae therelationshipbetweenantipsychotictreatmentandplasmabetaendorphinconcentrationinpatientswithschizophrenia
AT smigielskij therelationshipbetweenantipsychotictreatmentandplasmabetaendorphinconcentrationinpatientswithschizophrenia
AT urbankowalczykm relationshipbetweenantipsychotictreatmentandplasmabetaendorphinconcentrationinpatientswithschizophrenia
AT kotlickaantczakm relationshipbetweenantipsychotictreatmentandplasmabetaendorphinconcentrationinpatientswithschizophrenia
AT strzeleckid relationshipbetweenantipsychotictreatmentandplasmabetaendorphinconcentrationinpatientswithschizophrenia
AT rudeckae relationshipbetweenantipsychotictreatmentandplasmabetaendorphinconcentrationinpatientswithschizophrenia
AT smigielskij relationshipbetweenantipsychotictreatmentandplasmabetaendorphinconcentrationinpatientswithschizophrenia
_version_ 1718394500991156224